Corticosteroids in inflammatory bowel disease: Are they still a therapeutic option?
Corticoides en la enfermedad inflamatoria intestinal: ¿siguen siendo una opción terapéutica?
Atención de salud
Budesonida
Budesonide
Corticoesteroides
Corticoides
Corticosteroids
Enfermedad inflamatoria intestinal
Health care
Inflammatory bowel disease
Steroids
Tratamiento
Treatment
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
09
07
2022
revised:
26
10
2022
accepted:
30
10
2022
medline:
27
10
2023
pubmed:
15
11
2022
entrez:
14
11
2022
Statut:
ppublish
Résumé
Despite the development and incorporation of new therapeutic strategies, such as biologic therapy and small molecules, corticosteroids still play an important role in inducting inflammatory bowel diseases (IBD) remission. Variables like indicating the right doses at the right time, in adequate intervals, the security of these drugs and the pharmacological alternatives available must be considered by the providers when they are indicated to patients with IBD. Although the use of corticosteroids is considered as a marker of quality of care in patients with IBD, the use of these drugs in the clinical practice of IBD is far from being the correct one. This review article is not intended to be just a classic review of the indications for corticosteroids. Here we explain the scenarios in which, in our opinion, steroids would not be an appropriate option for our patients, as well as the most frequent mistakes we make in our daily practice when using them.
Identifiants
pubmed: 36375697
pii: S0210-5705(22)00263-1
doi: 10.1016/j.gastrohep.2022.10.017
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
716-726Informations de copyright
Copyright © 2022 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.